



A Dynamic Leader  
in the Global  
Pharmaceutical  
Marketplace




#### Global Headquarters

Actavis, Inc.  
Morris Corporate Center III  
400 Interpace Parkway  
Parsippany, NJ 07054

#### International Headquarters

Actavis  
Turmstrasse 24  
6300 Zug  
Switzerland  
NYSE:ACT [www.actavis.com](http://www.actavis.com)





## A Dynamic Leader in the Global Pharmaceutical Marketplace

Actavis Pharma, formerly known as our Global Generics business, holds leadership positions in a number of markets, including the U.S. and throughout Europe and Asia/Pacific. Actavis Specialty Brands, previously known as Watson Global Brands, is a leader in Women's Health and Urology in the U.S., has expanded into Canada and Latin America and is pursuing opportunities to bring distinctive brand products to markets outside the Americas.

We develop and out-license generic pharmaceutical products outside the U.S. through our third-party business, Medis. As the world's leading generic pharmaceutical out-licensing company, Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products. We are also aggressively pursuing the development of biosimilars internally and through our biosimilars collaboration with Amgen.

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.


Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories, and is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Andia, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.






## Our Global Marketplace

Actavis has operations in more than 60 countries, and is among the leaders in key markets including the United States, Canada, Western Europe, Central and Eastern Europe, Russia, Southeast Asia and Australia.




## Future Growth through Research and Development

Actavis is committed to developing generic and brand pharmaceuticals products, as well as biosimilars that will drive future growth. Our R&D activities focus on products using solid dosage form, oral controlled and sustained release, transdermal, injectable, gel, semi-solid and oral transmucosal technologies.



## Exceptional Service Driven by Unparalleled Global Supply Chain

Our industry-leading global supply chain includes finished dosage form manufacturing, as well as active pharmaceutical ingredient (API) development and manufacturing. We also have biosimilars capabilities headquartered at our state-of-the-art center located in Liverpool, UK and through a collaboration with Amgen.



# Our People – Committed to Leadership

## Our Mission

We develop and manufacture pharmaceuticals of the highest quality. We meet current and future customer needs through smart investments in R&D. We deliver best-in-class service and superior value. We celebrate the many cultures of our global team. We enhance the communities in which we live and work. We build shareholder value in all we do.

Our global team of passionate and dedicated scientists, technicians, sales and marketing, administrative, manufacturing and other business professionals work together to achieve our global mission.





## Actavis by the Numbers

Truly diverse footprint in

**60+ Countries**

**~32** manufacturing facilities;  
**~44 billion** unit capacity

**Strong** position in generic oncology  
injectables

Broad **product** line

Strong **semi-solids** and  
**liquids** capability

Broad **OTC** presence

**10%** market share in U.S.

**16+** global R&D centers

